The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Longer-term follow up of a phase 1 study of ponatinib in patients (pts) with Philadelphia chromosome-positive (Ph+) leukemias.
Moshe Talpaz
Consultant or Advisory Role - ARIAD; Novartis
Honoraria - ARIAD
Research Funding - ARIAD; Bristol-Myers Squibb; Novartis; Pfizer
Jorge E. Cortes
Consultant or Advisory Role - ARIAD; Bristol-Myers Squibb; Pfizer; Teva
Research Funding - ARIAD; Bristol-Myers Squibb; Novartis; Pfizer; Teva
Hagop M. Kantarjian
Research Funding - ARIAD; Bristol-Myers Squibb; Novartis; Pfizer
Neil P. Shah
Consultant or Advisory Role - ARIAD; Bristol-Myers Squibb
Research Funding - ARIAD; Bristol-Myers Squibb
Dale L. Bixby
Honoraria - ARIAD
Ian Flinn
Research Funding - ARIAD
Thomas O'Hare
No relevant relationships to disclose
Simin Hu
Employment or Leadership Position - ARIAD
Stock Ownership - ARIAD
Victor M. Rivera
Employment or Leadership Position - ARIAD
Stock Ownership - ARIAD
Tim Clackson
Employment or Leadership Position - ARIAD
Stock Ownership - ARIAD
Christopher D. Turner
Employment or Leadership Position - ARIAD
Stock Ownership - ARIAD
Frank G. Haluska
Employment or Leadership Position - ARIAD
Consultant or Advisory Role - ARIAD
Stock Ownership - ARIAD
Research Funding - ARIAD
Brian J Drucker
Consultant or Advisory Role - Ambit BioSciences; AstraZeneca; Avalon Pharma; Bioexpertise; Blueprint Medicines; Calistoga Pharmaceuticals; Cell Therapeutics; Cylene; Geron; Gilead Sciences; kereos; Lilly; Lorus; Millennium; Nodality; Prolexys; Roche; SGX; UCB
Stock Ownership - Blueprint Medicines; MolecularMD
Honoraria - Agios; GlaxoSmithKline; Pfizer
Research Funding - Bristol-Myers Squibb; Novartis
Other Remuneration - ARIAD; Bristol-Myers Squibb; MolecularMD; Novartis
Michael W.N. Deininger
Consultant or Advisory Role - ARIAD; Bristol-Myers Squibb; Incyte; Novartis
Honoraria - ARIAD; Bristol-Myers Squibb; Incyte; Novartis
Research Funding - Bristol-Myers Squibb; Celgene; Genzyme; Novartis; YM BioSciences
Michael J. Mauro
Consultant or Advisory Role - ARIAD